Neurocysticercosis Clinical Trial
Official title:
Establishment and Application of a Taenia Solium Experimental Pig Infection Model and Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Eastern and Southern Provinces of Zambia
This study aims to determine the prevalence of taeniosis and (neuro)cysticercosis in two districts in the southern (Gwembe) and eastern province (Chipata) of Zambia.
The true prevalence of Neurocyticercosis in Zambia is not well known. Only one study which was a pilot study done in Katete district of eastern province demonstrated the prevalence of NCC among people with epilepsy. There is need to provide an accurate estimate of the prevalence of NCC among people with cysticercosis in Zambia as well as understand the clinical manifestations of the disease in humans. Data on the full range of clinical characteristics of NCC is essential to accurately estimate the burden of the disease in the community. The epidemiology work package within the human health sector will create awareness of the size of the problem by delivering scientifically generated prevalence data on TSCT and NCC in various population groups (adults, children, and those living with epilepsy) in two provinces of Zambia. This will form an essential prerequisite for the development of public health policy guidelines for the control/elimination of TSCT/NCC in the country. Further, environmental factors that could play a role in the transmission and maintenance of T. solium eggs will be studied. This will provide essential data in understanding the epidemiology of the parasite in endemic regions. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00526916 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
|
Phase 1 | |
| Completed |
NCT00527579 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
|
Phase 1 | |
| Terminated |
NCT02233855 -
People Presenting With Neurocysticercosis in North America
|
||
| Completed |
NCT02234570 -
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
|
Phase 1 | |
| Terminated |
NCT02947581 -
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
|
Phase 3 | |
| Not yet recruiting |
NCT06376396 -
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
|
Phase 4 | |
| Completed |
NCT02243644 -
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
|
Phase 3 | |
| Completed |
NCT00441285 -
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04706819 -
Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
|
||
| Completed |
NCT00283699 -
A Pilot Study of Neurocysticercosis Treatment
|
Phase 3 | |
| Terminated |
NCT02945527 -
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
|
Phase 2/Phase 3 | |
| Completed |
NCT00290823 -
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
|
Phase 3 | |
| Completed |
NCT03834337 -
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
|
||
| Completed |
NCT03851419 -
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
|